Delayed London S.E. 07:34:56 2024-04-18 am EDT 5-day change 1st Jan Change
12.1 GBX -1.27% Intraday chart for ANGLE plc -12.04% +2.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ANGLE plc Presents Parsortix HER2 Assay at AACR Annual Meeting 2024 CI
Transcript : ANGLE plc - Special Call
Angle highlights supportive data for DNA analysis tool AN
Stocks up ahead of US nonfarm payrolls AN
Angle shares soar following "breakthrough" cancer diagnostics results AN
Retailers Next and JD Sports bookend FTSE 100 AN
AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up AN
Next leads buoyant FTSE 100 amid services PMIs AN
Angle Plc Outlines 'Breakthrough' Results from DNA Molecular Analysis of Cancer Patient Blood Samples; Stock Soars MT
ANGLE plc Announces Clinical Results Provide A Unique Insight into the Progression of Each Patient's Cancer CI
Angle PLC Shares Rise on Cancer Patient Blood Sample Analysis DJ
Angle teams with Japan's Eisai in breast cancer drug trial AN
Angle plc Signs Contract with Eisai on Breast Cancer Study MT
Angle plc Signs Contract with Eisai Inc CI
Ondine Biomedical raises GBP2.9 million via placing AN
Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery CI
Angle launches diagnostic kit at cancer symposium AN
ANGLE plc Launches Portrait+ CTC Kit At SABCS CI
FTSE 100 Ends Three-Day Falling Streak After Mixed Updates DJ
Angle says build up of revenue slower than hoped; launches test AN
ANGLE plc Provides Earnings Guidance for the Year 2023 CI
ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation CI
Franchise Brands trading in line; Tribe secures loan AN
Angle hails study which shows Parsortix outperforming lab standard AN
Angle plc Announces Publication of Study of Disseminated Tumour Cells in Bone Marrow from Breast Cancer Patients Published in the International Journal of Molecular Sciences CI
Chart ANGLE plc
More charts
ANGLE plc is a United Kingdom-based liquid biopsy company. The Company is engaged in the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy-non-invasive cancer diagnostics. Its platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for highly multiplexed analysis of nucleic acids and proteins. Its Parsortix PC1 Clinical system captures and harvests circulating CTCs from metastatic breast cancer patients blood for subsequent, user-validated analysis. The Parsortix PC1 Clinical System is a liquid biopsy technology. Its labs in Guildford provide specialist CTC enrichment and analysis services to support translational research studies and pharmaceutical trials. It has developed the Parsortix system, including instruments and one-time use cassettes that can be sold to third-party laboratories for their use in research, pharmaceutical development, or clinical use.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1225 GBP
Average target price
0.685 GBP
Spread / Average Target
+459.18%
Consensus
  1. Stock Market
  2. Equities
  3. AGL Stock
  4. News ANGLE plc
  5. Angle Flags Delay in Ovarian Cancer Study Due to Supply Chain Issues